Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics and Safety of KRN7000 Following Intravenous Infusion of RGI-2001 in Allogeneic Transplant Patients

Yi-Bin Chen, MD, Dana D Lee, PharmD, Hayley Lane, Steve Smith, Yasuyuki Ishii, PhD, Lazaros J. Lekakis, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-141526

Published: 2020

Journal Articles

Liposomal Alpha-Galactosylceramide Ameliorates Graft-Versus-Host Disease with Remaining Intensified GVL Gained By Dose-Reduction of Posttransplant Cyclophosphamaide after Haploidentical HSCT

Makoto Nakamura, MD, Ken-ichi Matsuoka, MDPhD, Yusuke Meguri, MD, Shuntaro Ikegawa, MD, Hiroyuki Sugiura, MD, Yasuhisa Sando, MD, Miki Iwamoto, Takeru Asano, MD, Yasuyuki Ishii, PhD, Yoshinobu Maeda, MDPhD

Blood (2017) 130 (Supplement 1): 1897.

https://doi.org/10.1182/blood.V130.Suppl_1.1897.1897

Published: 2017

Journal Articles

Protection of Factor VIII-Specific IgG Antibody Response and IgE Formation By Pretreatment with Liposomal α-Galactosylceramide in the Enzyme Replacement Therapy Mouse Model

Hidetoshi Akimoto, PhD, Emi Fukuda-Kawaguchi, PhD, Omar Duramad, PhD, Yasuyuki Ishii, PhD

Blood (2016) 128 (22): 2522.

https://doi.org/10.1182/blood.V128.22.2522.2522

Published: 2016

Journal Articles

Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death Via Large Pore Formation

Shuji Matsuoka, MDPhD, Yasuyuki Ishii, PhD, Atsuhito Nakao, MDPhD, Hiroshi Masutani, Satoshi Takahashi, MD PhD, Yusuke Nakauchi, MD, Okio Hino, MDPhD

Blood (2014) 124 (21): 5488.

https://doi.org/10.1182/blood.V124.21.5488.5488

Published: 2014

Journal Articles

Liposomal KRN7000 (RGI-2001) Synergizes with Low-Dose Rapamycin in Preventing GvHD by promoting expansion of naturally-Occurring CD4 + FOXP3 + Regulatory T Cells.

Omar Duramad, Amy Laysang, Jun Li, Tuyen Trinh, M.P.H, Yasuyuki Ishii, Reiko Namikawa, MD, PhD

Blood (2009) 114 (22): 4491.

https://doi.org/10.1182/blood.V114.22.4491.4491

Published: 2009

Journal Articles

A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4 + Foxp3 + Regulatory T Cells in Murine Models

Omar Duramad, PhD, Amy Laysang, Jun Li, Natalie Nguyen, Yasuyuki Ishii, PhD, Reiko Namikawa, MD, PhD

Blood (2008) 112 (11): 3500.

https://doi.org/10.1182/blood.V112.11.3500.3500

Published: 2008

Journal Articles

Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001).

Omar Duramad, PhD, Amy Laysang, Jun Li, Yasuyuki Ishii, PhD, Reiko Namikawa, MD, PhD

Blood (2008) 112 (11): 2332.

https://doi.org/10.1182/blood.V112.11.2332.2332

Published: 2008

NARROW

Pharmacokinetics and Safety of KRN7000 Following Intravenous Infusion of RGI-2001 in Allogeneic Transplant Patients

Liposomal Alpha-Galactosylceramide Ameliorates Graft-Versus-Host Disease with Remaining Intensified GVL Gained By Dose-Reduction of Posttransplant Cyclophosphamaide after Haploidentical HSCT

Protection of Factor VIII-Specific IgG Antibody Response and IgE Formation By Pretreatment with Liposomal α-Galactosylceramide in the Enzyme Replacement Therapy Mouse Model

Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death Via Large Pore Formation

Liposomal KRN7000 (RGI-2001) Synergizes with Low-Dose Rapamycin in Preventing GvHD by promoting expansion of naturally-Occurring CD4 + FOXP3 + Regulatory T Cells.

A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4 + Foxp3 + Regulatory T Cells in Murine Models

Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001).

Email alerts

ASH Publications

American Society of Hematology

Pharmacokinetics and Safety of KRN7000 Following Intravenous Infusion of RGI-2001 in Allogeneic Transplant Patients

Liposomal Alpha-Galactosylceramide Ameliorates Graft-Versus-Host Disease with Remaining Intensified GVL Gained By Dose-Reduction of Posttransplant Cyclophosphamaide after Haploidentical HSCT

Protection of Factor VIII-Specific IgG Antibody Response and IgE Formation By Pretreatment with Liposomal α-Galactosylceramide in the Enzyme Replacement Therapy Mouse Model

Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death Via Large Pore Formation

Liposomal KRN7000 (RGI-2001) Synergizes with Low-Dose Rapamycin in Preventing GvHD by promoting expansion of naturally-Occurring CD4 + FOXP3 + Regulatory T Cells.

A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4 + Foxp3 + Regulatory T Cells in Murine Models

Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only